(redirected from Fluorodeoxyglucose)
Also found in: Medical, Wikipedia.
FDGFriedrich Dessauer Gymnasium (Germany)
FDGFoundations of Digital Games
FDGFly Dressers Guild (UK)
FDGFundação de Desenvolvimento Gerencial
FDGFederazione Diabete Giovanile (Italian: Juvenile Diabetes Federation)
FDGForces Démocratiques de la Guyane (French: Guyana Democratic Forces)
FDGFranchise Development Group
FDGFrance Distribution Gestion (French distribution company)
FDGF-18-Deoxyglucose or Fluorodeoxyglucose (radiopharmaceutical)
FDGFood & Drink Group (various organizations)
FDGFunction Dependence Graph
FDGFunctional Dependency Gate
FDGFront des Gaulois
FDGFalling Down Giggling
FDGFamily Dental Group, PC
FDGF-Labeled 2-Deoxyglucose
FDGFraud Detection Group
References in periodicals archive ?
Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
Biomarkers included fluorodeoxyglucose positron emission tomography (FDG-PET), magnetic resonance imaging and measures of beta amyloid and tau found in cerebrospinal fluid (CSF).
Positive biomarkers, such as altered levels of beta-amyloid or high levels of tau in the cerebrospinal fluid, PET scans that reveal amyloid buildup in the brain, brain atrophy revealed on MRI, or changes in brain activity revealed on fluorodeoxyglucose PET scans.
F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
Fluorodeoxyglucose positron emission tomography plus computed tomography (FDG PET/CT) allows the early detection of inflammatory breast cancer, particularly the detection of sites of distant metastases.
A new study conducted by the American College of Radiology Imaging Network (ACRIN(r)) and the Gynecologic Oncology Group (GOG) is now underway to evaluate the ability of positron emission tomography (PET)/computed tomography (CT) with Fluorodeoxyglucose (FDG-PET/CT) and MRI with the contrast agent Combidex (ferumoxtran-10) to identify pelvic and abdominal lymph node metastases in patients with locoregionally advanced cervical cancer.
The new system, which will use as imaging agents not only fluorodeoxyglucose (FDG) but also water, oxygen, carbon dioxide and carbon monoxide, can observe the blood flow and oxygen consumption of the brain and heart on a real-time basis.
Traditionally, PET employs a labeled version of the sugar glucose, called fluorodeoxyglucose (FDG).
Positron emission tomographic scan showed no uptake of F-18 fluorodeoxyglucose in the nodule, lungs, or mediastinum.